PDE

These include the brokers semaxinib [80], sunitinib [81, 82], tandutinib [83] and KW-2449 [84]

These include the brokers semaxinib [80], sunitinib [81, 82], tandutinib [83] and KW-2449 [84]. chemotherapy. Factors such as sustained FLT3 inhibition, protein binding, pharmacokinetics, and the presence of elevated FLT3-ligand levels appear to significantly impact the potency of these brokers Most of these compounds are structural mimics of the purine component of ATP, and occupy …